Compare CHKP & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHKP | NBIX |
|---|---|---|
| Founded | 1993 | 1992 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 13.2B |
| IPO Year | 1997 | 1996 |
| Metric | CHKP | NBIX |
|---|---|---|
| Price | $135.87 | $130.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 22 |
| Target Price | ★ $205.75 | $180.82 |
| AVG Volume (30 Days) | 782.2K | ★ 901.1K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 4.67 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $8.28 | $22.85 |
| Revenue Next Year | $6.03 | $10.36 |
| P/E Ratio | ★ $17.05 | $27.09 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $134.38 | $97.30 |
| 52 Week High | $233.78 | $160.18 |
| Indicator | CHKP | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 50.14 |
| Support Level | N/A | $124.29 |
| Resistance Level | $208.46 | $136.23 |
| Average True Range (ATR) | 5.23 | 4.29 |
| MACD | -0.17 | -0.08 |
| Stochastic Oscillator | 4.38 | 59.64 |
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.